Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205159 | 0.91 | PLA2G2A (0.31) | PLA2G2AKDM4EMEN1KMT2A | |
| SCHEMBL3454178 | 0.73 | GABRA1 (0.42) | MAPTMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL1011868 | 0.67 | MAPK1 (0.41) | MAPTMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL985213 | 0.66 | TSHR (0.44) | KDM4EKMT2A | |
| SCHEMBL2395983 | 0.66 | GABRA1 (0.36) | MAPTKDM4EMEN1KMT2A | |
| SCHEMBL11068459 | 0.64 | THRB (0.42) | MAPTMAPK1PTGDRPTGDR2 | |
| SCHEMBL6510223 | 0.61 | GABRA1 (0.36) | MAPTKDM4EMEN1KMT2A | |
| SCHEMBL861238 | 0.61 | KDM4E (0.51) | KDM4E | |
| SCHEMBL3457708 | 0.61 | CTNNB1 (0.52) | MAPTMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL5921945 | 0.61 | CTNNB1 (0.49) | MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678782-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7144877-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1358200-A4 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1358200-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | Xenoport, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020099041-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2002-07-25 | — | — | US | disclosed |
| WO-2002044324-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | PLA2G2A 441/4885MAPT 2118/4885MAPK1 4657/4885 |
| US-20020099041-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | PLA2G2A 441/4885MAPT 2118/4885MAPK1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.